CVRx, Inc. (CVRX) Stock

CVRx, Inc. (CVRX) is a Healthcare stock trading at $2.83 (as of 2026-08-20), with a market capitalization of $75.53M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

CVRx, Inc. develops, manufactures, and commercializes neuromodulation devices for people with cardiovascular diseases, including its Barostim system for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells in the United States, Germany, the rest of Europe, and internationally through a direct sales force, sales agents, and independent distributors.

Understand CVRx, Inc.: how it makes money

CVRx develops and sells Barostim neuromodulation devices for patients with heart failure, and it makes money from product sales through a direct sales force, sales agents, and independent distributors.

The profit model depends on scaling Barostim adoption, which is reflected in the growth of Active Implanting Centers and the resulting heart failure device sales, while current operating results remain heavily loss-making relative to revenue.

Revenue by segment (latest quarter)
U.S.$0.0B
Europe$0.0B

Business quality (Weak): Segment information provided here is limited to revenue by geography, and the company is still in a commercialization stage with a very negative operating margin.

Bull case

  • Adoption footprint is tracked by implanting centers: Key operating metrics include Active Implanting Centers (United States) and Net New Active Implanting Centers, which can indicate how quickly Barostim is being adopted by treating physicians.
  • High gross margin suggests product economics before operating expenses: The latest-quarter gross margin is 87.2%, which indicates strong gross profitability at the product level even though operating results are still deeply negative.

Bear case

  • Operating losses are large relative to revenue: The latest-quarter operating margin is -82.3%, which shows costs exceed gross profit by a wide margin.
  • Geographic revenue concentration: In the provided segment candidates for the latest quarter, United States revenue is about 0.01B while Europe revenue is 0.0B, which implies limited contribution from Europe in this snapshot.
Valuation — source: SEC EDGAR (first-party)
Price$2.83
Market Cap$75.53M
Price / Book3.79
Price / Sales1.23
FCF Yield-54.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$56.65M
Net Margin-94.1%
Revenue Growth (YoY)15.6%
EPS Growth (YoY)-7.0%
FCF Growth (YoY)11.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-7.27 (distress)
Piotroski F-Score3/9 (weak)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJOHNSON & JOHNSON ($38.08M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOKevin Hykes
Employees206
CountryUS
IPO Date2021-06-30

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Femasys Inc. (FEMY)
  • Apyx Medical Corporation (APYX)
  • Microbot Medical Inc. (MBOT)
  • Pulmonx Corporation (LUNG)
  • Sharps Technology, Inc. (STSS)
  • DarioHealth Corp. (DRIO)
  • Spectral AI, Inc. (MDAI)
  • Nephros, Inc. (NEPH)
CVRX earnings history · CVRX institutional & insider holders · CVRX KPIs & operating metrics · CVRX financials · CVRX investor presentations & press releases · CVRX SEC filings · CVRX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.